Longevity supplement shows no benefit in Parkinson's trial
A trial found no significant clinical benefit from nicotinamide riboside in early Parkinson's disease. The NOPARK trial tested the supplement's effect on disease progression.
People with Parkinson's and those considering supplements may want to know the trial's limitations and next steps.
- population
- early Parkinson's disease
Taken from the source as published — check the details before acting on them.
Trial design and outcome
The NOPARK trial was a randomized study assessing nicotinamide riboside's impact on Parkinson's progression, but found no significant effect.
What was tested
The supplement, a form of vitamin B3, was studied for its potential to increase NAD+ levels and slow disease progression.
Common questions
What was the purpose of the trial?
The trial aimed to assess whether nicotinamide riboside could slow the progression of early Parkinson's disease.
Sources
- Popular Longevity Supplement Fails to Meet Endpoint in Parkinson's Trial MedPage Today · medpagetoday.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
